To elaborate on the concept of superhuman vaccine immunity:
Each of the 3 examples in our piece are for different reasons. 1. HPV—best, since the human response is weak 2. Tetanus—small amounts of toxin don't elicit strong response) 3. H Flu—the bacterium is sugar coated
2/
This is different from vaccine efficacy.
Take measles. The natural human response to infection provides durable efficacy but the vaccine requires multiple shots and is without lifelong protection. 3/
Superhuman vaccine = superior to typical human response to natural infection
The #SARSCoV2 neutralizing antibody response to mRNA vaccines has exceeded that of many convalescent patients by orders of magnitude @NEJMbit.ly/33ys84T 4/
The natural human response to #COVID19 infection leaves many patients without a full and/or durable immune response, as nicely depicted (G=IgG, B=B cells, 4=CD4, 8=CD8, A=IgA) biorxiv.org/content/10.110… Figure 5C @profshanecrotty and colleagues 5/
Several #SARSCoV2 reinfections have been documented in patients without a sufficient IgG antibody response to the primary infection bnonews.com/index.php/2020… 6/
There are still many unknowns about the mRNA (and other platform) #SARSCoV2 vaccines with respect to durability, sterilization immunity (that would prevent transmission) and the role of T cells. 7/
In sum, the results to date suggest #SARSCoV2's spike protein lays the foundation for a potent vaccine-induced immune response that will turn out to be superior to that derived from natural infections. 8/
I recently spoke to @DrPaulOffit about the concept of a superhuman vaccine immune response medscape.com/viewarticle/93…
He highlighted the #SARSCoV2 inhibition of our interferon response and this point👇
And cited the 3 prototypic examples
• • •
Missing some Tweet in this thread? You can try to
force a refresh
We're learning how to control the immune response, like a rheostat, even in the brain. Implications for understanding the basis and potential treatment of autoimmune conditions like multiple sclerosis, #LongCovid, #MECFS, and brain cancer.
A brief review of 6 recent, important reports
in the new Ground Truths, open-access
Such as Programming T cells with brain-specific proteins and payloads
@ScienceMagazine science.org/doi/10.1126/sc…
Or peptide fragments of myelin basic protein that suppress the immune response @Nature nature.com/articles/s4158…
New @NEJM
A whopping (~90%) reduction of progression to Type 2 diabetes with tirzepatide (GLP-1 drug, dual receptor) vs placebo in a randomized trial of >2,500 participants with obesity, absolute reduction of 10/100 treated
In other GLP-1 new publications today
—Country-wide Sweden reduced hospitalizations for alcohol or substance abuse with these drugs jamanetwork.com/journals/jamap… @JAMAPsych
—Concerns about discontinuation jamanetwork.com/journals/jama/… @JAMA_current
Other new anti-obesity drugs in the pipeline, one that also increases energy expenditure
@NatureNV nature.com/articles/d4158…
A dedicated issue of @ScienceTM on #LongCovid
—Sex-specific differences, with perspective by @VirusesImmunity and @SilvaJ_C
—Insights for therapies @AndreaCoxMDPhD
—Deconvoluting "Osler's Web" @MichaelPelusoMD @DeeksSteven @DrMaureenHanson @SaydahSharon
—+RECOVER Trial, Lyme disease
An elegant @Nature study by @AkassoglouLab has illuminated our understanding of the role of fibrin (component of blood clots), #SARSCoV2, and brain inflammation in Covid and #LongCovid.
This discovery and more in the new Ground Truths podcast, with transcript, key figures (such as as the one below) and citations. Open-access. Link in my profile.
A clip from our conversation. Unknowingly, @AkassoglouLab was gearing up for understanding this complex pathophysiology for many years before Covid hit
For treatment, it's not just as simple as preventing fibrin clots. It's isolating the pro-inflammatory action of fibrin, targeted by the antibody
Covid and increased risk of major adverse cardiovascular events (MACE) 3-years out
2-fold increased for any severity of Covid
~4-fold increase for Covid requiring hospitalization
"a coronary artery disease equivalent"
interaction with non-O blood types
@uk_biobankahajournals.org/doi/10.1161/AT…
"A major finding from our analyses was that the risk
of MACE among the subset of hospitalized COVID-
19 cases without known CVD (ie, primary prevention
patients) was comparable to (or even slightly higher than) the risk in patients with CVD, PAD, or diabetes but without COVID-19."
"one of the first examples of a gene-pathogen exposure interaction for thrombotic events"
I think it's the first one documented, likely others to be unraveled
New US Covid genomic surveillance
The KP.3.1.1 variant is on the move to become dominant, more of a challenge to our immune response than KP.3 and prior variants (especially without new KP.2 booster when we need it for high-risk individuals)
It's the deletion 31/31 that makes the KP.3.1.1 spike different, but otherwise 2 mutations away from KP.2 (R346T and Q493E)
Buckle up; this wave isn't over yet d/t KP.3.1.1's emergence